In a retrospective, observational clinical study, 63 nonresponders from 527 RA patients treated with tocilizumab were switched to TNF inhibitors (infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol) or abatacept. Here, TNF is linked to rheumatoid arthritis.